ArticleCureus2025
Hemoptysis Revealing Microscopic Polyangiitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microscopic polyangiitis (MPA) is a rare, necrotizing vasculitis affecting small-caliber vessels, commonly associated with anti-neutrophil cytoplasmic antibodies (ANCA), particularly anti-myeloperoxidase (MPO). We report the case of a 63-year-old male with a medical history of chronic smoking and hypothyroidism, who presented with hemoptysis, worsening dyspnea, and constitutional symptoms. Imaging revealed bilateral alveolo-interstitial infiltrates indicative of lung involvement, along with a distal pulmonary embolism. Laboratory investigations found anemia, rapidly progressive renal impairment, and positive anti-MPO perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) at high titers, supporting a diagnosis of MPA. The patient was treated with high-dose corticosteroids and cyclophosphamide, with the immunosuppressive therapy adjusted according to his renal function. This case highlights the importance of considering MPA in patients with unexplained pulmonary and renal manifestations, especially in the presence of constitutional symptoms and positive ANCA serology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.